Cytokine-Secreting CAR-T Development Service for Solid Tumor Targeting

Creative Biolabs offers a Cytokine-Secreting CAR-T Development Service for solid tumor targeting, addressing challenges such as poor tumor infiltration, T cell exhaustion, and the immunosuppressive tumor microenvironment (TME). By leveraging advanced synthetic biology and precise cytokine/chemokine expression, we engineer robust armored CAR-T cells that enhance persistence, tumor homing, and antitumor efficacy, providing a streamlined path to next-generation, highly effective CAR-T therapies for solid tumors.

Introduction

Cytokine-Secreting CAR-T technology, also known as TRUCK-T (T cells Redirected for Universal Cytokine-Mediated Killing), represents the fourth generation of CAR-T therapy. This innovation is particularly crucial for treating solid tumors, where CAR-T cell function is often hindered by T cell exhaustion, poor tumor infiltration, and an immunosuppressive microenvironment. By genetically engineering T cells to carry a therapeutic payload (X), such as a cytokine, a chemokine, or an enzyme, the cells become targeted, localized therapeutic delivery systems.

Service

Creative Biolabs offers a comprehensive solution, enabling the creation of advanced CAR-T cell products engineered to overcome the core limitations of immunotherapy in solid tumors: immune exclusion and immunosuppression. We transform first-generation CAR-T cells into multi-functional agents (the CAR+X strategy). The specific deliverables include generating novel CAR constructs that encode both the CAR and a therapeutic payload (the X factor) for localized activity. We provide the critical pathway to achieving efficacy in previously refractory cancer types, including those prone to antigen loss and dense stroma.

Discover How We Can Help - Request a Consultation.

Technology Components

Workflow: Precision Engineering and Validation

The process is meticulously structured to ensure precision, control, and therapeutic viability for your novel CAR-T candidate. The required starting materials include target antigen information with sequence and expression profile, the CAR scFv sequence and backbone format, and the rationale for cytokine or TME-modulating payload selection.

Core Benefits

• Enhanced CAR-T Persistence: Autocrine IL-7 or IL-15 promotes long-term CAR-T survival and proliferation.
• Improved Tumor Infiltration: Cytokine gradients guide T-cell trafficking into solid tumor cores.
• TME Repolarization: IL-12 or IL-18 secretion reshapes M2 macrophages and MDSCs into pro-inflammatory phenotypes.
• Synergistic Immune Activation: Local cytokine release recruits endogenous NK and CD8+ T cells for multi-layered anti-tumor responses.

Published data

This research aims to enhance CAR-T cell therapy for solid tumors by combining it with a CD40 agonist, which activates the immune system. Scientists engineered CAR-T cells to both target a tumor antigen and secrete anti-CD40 antibodies. These modified cells demonstrated superior memory formation, cytokine release, and tumor-killing ability in lab models.

Fig.1 Construction of car-t cells that secrete CD40 antibody.¹

FAQs

Related Services

• Dominant-Negative Receptor

  Creative Biolabs engineers dominant-negative receptor–modified CAR-T cells to block suppressive cytokine signaling in the tumor microenvironment, enhancing resistance to inhibition and sustaining potent antitumor activity in solid tumors.

• Switch Receptor

  Creative Biolabs develops switch receptor–equipped CAR-T cells that convert inhibitory cues into activating signals, boosting T-cell function, persistence, and therapeutic efficacy within highly immunosuppressive solid tumor settings.

Partner with Us

Creative Biolabs' Cytokine-Secreting CAR-T Development Service serves as your gateway to next-generation cell therapies that overcome the limitations of current oncology treatments. Our proprietary expertise in conditional expression, orthogonal signaling, and TME remodeling provides the scientific foundation needed to transform your CAR-T candidate into a potent, safe, and persistent therapeutic agent for solid tumors. Ready to discuss your project and explore how our advanced CAR+X technology can accelerate your pipeline? Our scientific team is available to provide detailed consultations tailored to your specific tumor targets and development goals. Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Zhang, Yajun et al. “Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.” Journal of translational medicine vol. 19,1 82. 18 Feb. 2021. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s12967-021-02750-4